Nabriva Therapeutics Prices Initial Public Offering

Nabriva Therapeutics AG announced today the pricing of its initial public offering of 9,000,000 American Depositary Shares (ADSs), representing 900,000 of its common shares, at a public offering price of $10.25 per ADS, before underwriting discounts.

All of the ADSs are being sold by Nabriva.  In addition, Nabriva has granted the underwriters an option for a period of 30 days to purchase up to 1,350,000 additional ADSs at the public offering price, less the underwriting discount.  Nabriva's ADSs have been approved for listing on the NASDAQ Global Market and are expected to begin trading under the ticker symbol "NBRV" on September 18, 2015.

Leerink Partners LLC and RBC Capital Markets, LLC are acting as joint book-running managers for the offering.  Needham & Company, LLC and Wedbush PacGrow are acting as co-managers.

The offering is being made only by means of a prospectus.  Copies of the prospectus may be obtained from: Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or by email at, or by phone at (800) 808-7525 FREE FREE, ext. 6124, or RBC Capital Markets, LLC, Attention: Equity Syndicate Department, 200 Vesey Street, 8th Floor, New York, NY 10281, or by email at equityprospectus(at), or by phone at (877) 822-4089 FREE FREE.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there by any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction.

About Nabriva Therapeutics AG
Nabriva is a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics.  Nabriva is developing its lead product candidate, lefamulin, to be the first pleuromutilin antibiotic available for systemic administration in humans.

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)